Medtronic Must Produce InFuse Docs In Securities Suit

Law360, New York (September 22, 2011, 4:53 PM EDT) -- After much back and forth, a Minnesota federal judge on Wednesday ordered Medtronic Inc. to turn over years of medical studies on the safety of the InFuse spinal graft as a class of shareholders tries to prove that the alleged off-label use of the device is what caused company stock to take a dive. 

U.S. District Judge Arthur J. Boylan partially granted the plaintiffs’ motion to compel Medtronics to produce studies on its InFuse spinal graft dating back to 2002, which they claimed the company sponsored...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.